Breakthrough T1D's First Clinical & Research Congress Brings Global T1D Community Together

After extensive planning, Breakthrough T1D is holding its inaugural Clinical & Research Congress this week in Philadelphia—the city where the organization was founded more than 50 years ago. The three-day event, running October 9–11, 2026, brings together a diverse group of stakeholders: T1D researchers and scientists, healthcare professionals, industry leaders, and community members whose lives have been shaped by Type 1 diabetes.

Philadelphia's reputation as a hub of medical innovation makes it a fitting venue for this groundbreaking meeting. The location underscores Breakthrough T1D's roots in the city while positioning it as an ideal place for global experts to convene, share research findings, and discuss the next generation of T1D treatments and technologies.

The congress will feature cutting-edge presentations on T1D discovery science, emerging technologies, and new treatment approaches. A key focus will be islet cell therapies—an area of active clinical investigation.

Dr. Piotr Witkowski, lead investigator at the University of Chicago, will present updates from a Breakthrough T1D-funded clinical trial testing Eledon's tegoprubart. Dr. Per-Ola Carlsson will also share findings from islet cell research, highlighting the progress being made in this promising area of T1D science.

A defining feature of this congress is that its scientific program has been shaped by input from the T1D community itself. This approach ensures that the lived experiences and priorities of people with T1D—patients, parents, and caregivers—remain central to the research and clinical work being presented and discussed.

By centering patient voice in the scientific agenda, the congress reflects a broader commitment to making sure that advances in T1D research and treatment directly serve the goal of improving the lives of people living with the condition.

The congress's scientific program is fully accredited. Healthcare professionals attending the event can earn up to 12.0 CEU/CME credits toward their licensure and certification requirements, making it a valuable opportunity for clinicians to stay current on the latest T1D research and clinical developments.

Origin: breakthrought1d.org (News report). Evidence: News report — unverified, pending corroboration. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.